- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- February 2021
- 420 Pages
United States
From €2291EUR$2,400USD£1,919GBP
- Report
- March 2019
- 17 Pages
Global
€9544EUR$10,000USD£7,996GBP
- Report
- March 2019
- 17 Pages
Global
€9544EUR$10,000USD£7,996GBP
- Report
- May 2022
- 83 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
- Book
- February 2024
- 592 Pages
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder (MDD). It is a synthetic form of the active metabolite of venlafaxine, an antidepressant. Desvenlafaxine is used to treat depression, anxiety, and other mental health disorders. It works by increasing the levels of serotonin and norepinephrine in the brain, which helps to improve mood and reduce symptoms of depression. Desvenlafaxine is available in both immediate-release and extended-release formulations. The extended-release formulation is used to treat depression in adults.
Desvenlafaxine is a relatively new drug in the mental disorders drugs market. It is generally well-tolerated and has fewer side effects than other antidepressants. It is also effective in treating depression in patients who have not responded to other antidepressants.
Some companies in the desvenlafaxine market include Pfizer, Mylan, and Sun Pharmaceuticals. Show Less Read more